Human Rotavirus Vaccine Market Analysis 2026

Global Human Rotavirus Vaccine Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Human Rotavirus Vaccine Market Report Description

We have various report editions of Human Rotavirus Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

Human Rotavirus Vaccine Market Insights Video

Major players involved in the market include Bharat Biotech, Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc., Merck & Co., Inc., BIOVIRx Inc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd. Among others.

News:

• Bharat Biotech's rotavirus vaccine received Prequalification from WHO

In August 2021, Bharat Biotech International Limited announced that Rotavac 5D, a variant of its Rotavac vaccine, has received Prequalification from the World Health Organization (WHO). Rotavac vaccine is used to prevent rotavirus which causes severe diarrhea and vomiting and is mostly found in children. This is an important step to further strengthen Bharat Biotech’s position to prevent infections that affect millions in the developing world.

• FDA Approved Fully Liquid Presentation of GSK’s Rotarix Vaccine to Prevent Gastroenteritis Caused by Rotavirus

In November 2022, GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has approved an oral-dosing applicator presentation liquid formulation of Rotarix which prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants. This new formulation was developed with the vision to make it more convenient for healthcare providers to prepare Rotarix by removing the need to reconstitute the vaccine dose at the point of time.

Top Companies Market Share in Human Rotavirus Vaccine Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

North America accounted for relatively the largest share of the human rotavirus vaccine market. The growth of the human rotavirus vaccine market in North America is fuelled by some key factors including the high prevalence of gastroenteritis and rising expenditure on healthcare. In North America, the prevalence of G1P[8] is relatively high due to the higher efficiency of Rotarix against infection caused by G1P[8]. G1P[8] rotaviruses are causing diarrheal infections in humans all over the world. On the other hand, Asia pacific is expected to grow at the fastest growth rate during the forecast period, as the rapidly growing population, increasing burden of diarrheal diseases in children, and advancements in medical care procedures. In the Asia Pacific region, government initiatives have been taken, where the rotavirus vaccine should be included in all national immunization programs, particularly in countries with high rotavirus gastroenteritis (RVGE) rates.

The current report Scope analyzes Human Rotavirus Vaccine Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.